Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results